IceCure Medical's ProSense® cryoablation system, the only FDA-cleared minimally invasive treatment for low-risk breast cancer, is gaining clinical adoption and sales momentum in the U.S. following FDA clearance in October 2025. The system was featured at the 2026 American Society of Breast Surgeons meeting, where leading breast surgeons shared positive experiences and discussed its role in reducing treatment intensity. The ASBrS updated guidelines now recommend cryoablation for select low-risk breast cancer patients, reflecting growing evidence of its safety and effectiveness. IceCure expects a 30% increase in U.S. revenue for ProSense® in Q1 2026 compared to the previous year, signaling broader acceptance and potential standard-of-care status for this less invasive treatment option.
Fury Gold Mines has restarted exploration and drilling activities at its Eau Claire project in Northern Quebec following a temporary halt due to a nearby wildfire. All personnel have safely returned, and operations resumed after confirming safe condi...
YieldMax announced weekly distributions for three of its Performance & Distribution Target 25 ETFs: MSST, NVIT, and TEST. Each ETF targets a 25% annual income level, with distributions scheduled for July 29, 2026. These ETFs use a call writing strate...
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Dimensional Fund Advisors Ltd. has disclosed ownership of 11,780,819 shares, representing a 1.26% stake in Prologis Inc as of July 24, 2026. This disclosure is made under the Takeover Code, indicating a significant investment position. The firm also ...
Man Group PLC has publicly disclosed holding a 1.63% interest in Senior Plc through cash-settled equity swaps as of July 24, 2026. This disclosure is made under Rule 8.3 of the UK Takeover Code, indicating a significant stake in the company. The posi...
